Subject(s)
Cardiomyopathies/diagnosis , Hair Diseases/genetics , Hand Dermatoses , Keratoderma, Palmoplantar , Ventricular Dysfunction, Left/diagnosis , Adult , Hand Dermatoses/genetics , Hand Dermatoses/pathology , Humans , Keratoderma, Palmoplantar/genetics , Keratoderma, Palmoplantar/pathology , MaleABSTRACT
BACKGROUND: Mohs micrographic surgery (MMS) is an effective treatment for certain non-melanoma skin cancers. Optical coherence tomography (OCT) is a biomedical imaging modality that permits high-resolution imaging of the epidermis and dermis with the potential to detect both healthy tissue and tumour. OCT may also provide a means of detecting and differentiating between the various histological subtypes of basal cell carcinomas (BCC) in vivo. OBJECTIVE: The aim of this prospective ex vivo study was to evaluate the efficacy of OCT in recognising healthy and pathological margins of excised BCC lesions and detecting different BCC subtypes. METHODS: Seventy-three subjects with biopsy-proven BCCs on the facial region undergoing MMS were recruited. Narrow clinically healthy margins of the skin surrounding the tumour were included in the excisional biopsy. Biopsies were scanned with the OCT instrument immediately ex vivo and processed to obtain horizontal Mohs frozen sections and compared with their corresponding OCT images. RESULTS: Histopathological analysis of 280 margins showed 232 tumour free margins and 48 tumour-involved margins. OCT showed very good sensitivity (81.2%) and specificity (94.3%) in detecting healthy from tumour-involved margins. OCT accuracy was 93.4%, and the intra- and inter-observer reliability was substantial (Kappa value ranged between 0.63-0.76). CONCLUSION: This study shows the accuracy of ex vivo OCT in identifying the margin status of BCCs of the head and neck region. Moreover, this modality has demonstrated good capability in distinguishing different BCC subtypes and the potential for in vivo in situ diagnostics.
Subject(s)
Carcinoma, Basal Cell/pathology , Mohs Surgery/methods , Skin Neoplasms/pathology , Tomography, Optical Coherence/methods , Adult , Aged , Aged, 80 and over , Female , Humans , Male , Margins of Excision , Middle Aged , Observer Variation , Prospective Studies , Reproducibility of Results , Sensitivity and SpecificityABSTRACT
We report a case of Epidermolysis Bullosa Acquisita (EBA) that presented as a diagnostic challenge. A 60-year-old Qatari lady presented with odynophagia, oral ulceration, and weight loss. Multiple physicians investigated her for over 6 months with a multitude of tests and serial gastroscopies, all of which failed to reach a conclusive diagnosis. Only after referral to a dermatologist and full body examination was diagnosis finally achieved. After reviewing the literature, we provide a summary of EBA and highlight the importance of comprehensive clinical reviews in order to avoid unnecessary morbidity.
Subject(s)
Acantholysis/pathology , Penile Diseases/pathology , Skin Diseases/pathology , Diagnosis, Differential , Humans , Male , Middle AgedABSTRACT
BACKGROUND: Organ transplant recipients (OTRs) have an increased risk of skin cancer. Treatment with azathioprine, commonly used in post-transplant immunosuppressive regimens, results in incorporation of 6-thioguanine (6-TG) into DNA. Mismatch repair (MMR)-defective cells are resistant to killing by 6-TG. Azathioprine exposure confers a survival advantage on MMR-defective cells, which are hypermutable and may therefore contribute to azathioprine-related nonmelanoma skin cancer, a phenomenon we have previously demonstrated in transplant-associated sebaceous carcinomas. The MSH2 protein is an important component of DNA MMR. The -6 exon 13 T>C MSH2 polymorphism is associated with impaired MMR, drug resistance and certain cancers. OBJECTIVES: To investigate (i) whether loss of MMR protein expression and microsatellite instability are over-represented in squamous cell carcinomas (SCCs) from OTRs on azathioprine compared with SCCs from immunocompetent patients, and (ii) whether the MSH2 -6 exon 13 polymorphism is over-represented in OTRs with skin cancer on azathioprine. METHODS: (i) Immunohistochemical staining was used to assess expression of the MMR proteins MSH2 and MLH1 in cutaneous SCCs from OTRs on azathioprine and from immunocompetent patients. (ii) Blood samples from OTRs on azathioprine with and without skin cancer were genotyped for the -6 exon 13 MSH2 polymorphism. RESULTS: (i) MSH2 and MLH1 protein expression was not altered in SCCs from OTRs on azathioprine and there was no difference in expression between SCCs from OTRs and immunocompetent patients. (ii) There was no association between MSH2 polymorphism genotype frequency and OTR skin cancer status. CONCLUSIONS: Despite previous findings in transplant-associated sebaceous carcinomas, defective MMR and the -6 exon 13 MSH2 polymorphism are unlikely to play a significant role in the development of SCC in OTRs on azathioprine.
Subject(s)
Carcinoma, Squamous Cell/genetics , DNA Mismatch Repair/genetics , MutS Homolog 2 Protein/genetics , Organ Transplantation/adverse effects , Skin Neoplasms/genetics , Adaptor Proteins, Signal Transducing/genetics , Adaptor Proteins, Signal Transducing/metabolism , Azathioprine/therapeutic use , Base Pair Mismatch/genetics , Biomarkers, Tumor/genetics , Biomarkers, Tumor/metabolism , Carcinoma, Squamous Cell/metabolism , Female , Humans , Immunosuppressive Agents/therapeutic use , Male , Microsatellite Instability , Middle Aged , MutL Protein Homolog 1 , MutS Homolog 2 Protein/metabolism , Nuclear Proteins/genetics , Nuclear Proteins/metabolism , Polymorphism, Genetic/genetics , Skin Neoplasms/metabolismABSTRACT
The immunosuppressant azathioprine is used to prevent graft rejection after organ transplantation. To investigate whether azathioprine-associated mutagenesis contributes to the high incidence of skin tumours in organ transplant recipients (OTRs), we analysed PTCH gene mutations in 60 basal cell carcinomas (BCC); 39 from OTRs receiving azathioprine and 21 from individuals never exposed to azathioprine. PTCH was mutated in 55% of all tumours, independent of azathioprine treatment. In both the azathioprine and non-azathioprine groups, transitions at dipyrimidine sequences, considered to indicate mutation by ultraviolet-B radiation, occurred frequently in tumours from chronically sun-exposed skin. In BCC from non-sun-exposed skin of azathioprine-treated patients, there was an over-representation of unusual G:C to A:T transitions at non-dipyrimidine sites. These were exclusive to the azathioprine-exposed group and all in the same TGTC sequence context at different positions within PTCH. Meta-analysis of 247 BCCs from published studies indicated that these mutations are rare in sporadic BCC and had never previously been reported in this specific sequence context. This study of post-transplant BCC provides the first indication that azathioprine exposure may be associated with PTCH mutations, particularly in tumours from non-sun-exposed skin.
Subject(s)
Azathioprine/adverse effects , Carcinoma, Basal Cell/genetics , Immunocompromised Host/genetics , Immunosuppressive Agents/adverse effects , Receptors, Cell Surface/genetics , Skin Neoplasms/genetics , Adult , Aged , Aged, 80 and over , Carcinoma, Basal Cell/chemically induced , Carcinoma, Basal Cell/immunology , Female , Graft Rejection/prevention & control , Humans , Male , Middle Aged , Mutation , Organ Transplantation/adverse effects , Patched Receptors , Patched-1 Receptor , Polymerase Chain Reaction , Skin Neoplasms/chemically induced , Skin Neoplasms/immunology , Sunlight/adverse effectsABSTRACT
BACKGROUND: Azathioprine is used to treat a variety of conditions and to prevent graft rejection in organ transplant recipients (OTRs). OBJECTIVES: To investigate clinically our previous finding that azathioprine metabolites interact with ultraviolet (UV) A radiation to form promutagenic oxidative DNA damage and to determine whether this may be causal or contributory to the development of excess skin cancers post-transplantation. METHODS: The clinical corollary of these data were investigated. Five patients were recruited and the minimal erythema dose (MED) for UVB, UVA and solar-simulated radiation (SSR) was determined for each person before, and at least 12 weeks after, starting azathioprine therapy. RESULTS: In all five patients azathioprine treatment was associated with an increased UVA and SSR sensitivity of the skin and a significant reduction in MEDs for UVA and SSR. We found no change in UVB-induced erythema or MED. In addition, we found that DNA from the skin of patients on azathioprine contains 6-thioguanine (6-TG). CONCLUSIONS: Our findings confirm the presence of DNA 6-TG in the skin of those taking therapeutic doses of azathioprine and provide support for the hypothesis that DNA damage occurs when DNA 6-TG interacts with UVA, resulting in abnormal cutaneous photosensitivity.
Subject(s)
Azathioprine/adverse effects , DNA Damage , Immunosuppressive Agents/adverse effects , Photosensitivity Disorders/chemically induced , Skin Neoplasms/etiology , Ultraviolet Therapy/adverse effects , Adult , Case-Control Studies , Dose-Response Relationship, Radiation , Epidermis/radiation effects , Female , Graft Rejection/drug therapy , Humans , Male , Middle Aged , Thioguanine/adverse effects , Treatment OutcomeABSTRACT
Human papillomavirus (HPV) infection is associated with genital malignancy and specific cutaneous malignancies. We report a case of an HPV-associated concurrent vulval intraepithelial neoplasia and periungual Bowen's disease in a young immunocompetent Afro-Caribbean woman with no known risk factors for either disease. HPV genotyping studies detected multiple alpha and beta papillomaviruses with concordance for HPV-34 [a high-risk (HR) mucosal type], and HPV-21 [an epidermodyslasia verruciformis (EV) type] in both vulval and finger tissue. Although the HR-mucosal viruses detected are likely to have a pathogenic role in vulval intraepithelial neoplasia, this is the first report of concordance for EV HPV types in both genital and nongenital skin premalignancies. This case, in the context of accumulating epidemiological and experimental data in cutaneous SCC, raises the question of whether EV HPV may contribute to vulval malignancy, and further study is merited.
Subject(s)
Bowen's Disease/virology , Fingers/virology , Papillomaviridae/isolation & purification , Papillomavirus Infections/virology , Skin Neoplasms/virology , Vulvar Neoplasms/virology , Adult , Female , HumansABSTRACT
BACKGROUND: Organ transplant recipients (OTR) are at high risk of developing nonmelanoma skin cancer and premalignant epidermal dysplasia (carcinoma in situ/ Bowen's disease and actinic keratoses). Epidermal dysplasia is often widespread and there are few comparative studies of available treatments. OBJECTIVES: To compare topical methylaminolaevulinate (MAL) photodynamic therapy (PDT) with topical 5% fluorouracil (5-FU) cream in the treatment of post-transplant epidermal dysplasia. METHODS: Eight OTRs with epidermal dysplasia were recruited to an open-label, single-centre, randomized, intrapatient comparative study. Treatment with two cycles of topical MAL PDT 1 week apart was randomly assigned to one area of epidermal dysplasia, and 5-FU cream was applied twice daily for 3 weeks to a clinically and histologically comparable area. Patients were reviewed at 1, 3 and 6 months after treatment. The main outcome measures were complete resolution rate (CRR), overall reduction in lesional area, treatment-associated pain and erythema, cosmetic outcome and global patient preference. RESULTS: At all time points evaluated after completion of treatment, PDT was more effective than 5-FU in achieving complete resolution: eight of nine lesional areas cleared with PDT (CRR 89%, 95% CI: 0.52-0.99), compared with one of nine lesional areas treated with 5-FU (CRR 11%, 95% CI: 0.003-0.48) (P = 0.02). The mean lesional area reduction was also proportionately greater with PDT than with 5-FU (100% vs. 79% respectively). Cosmetic outcome and patient preference were also superior in the PDT-treated group. CONCLUSIONS: Compared with topical 5-FU, MAL PDT was a more effective and cosmetically acceptable treatment for epidermal dysplasia in OTRs and was preferred by patients. Further studies are now required to confirm these results and to examine the effect of treating epidermal dysplasia with PDT on subsequent development of squamous cell carcinoma in this high risk population.
Subject(s)
Antimetabolites, Antineoplastic/therapeutic use , Carcinoma in Situ/drug therapy , Fluorouracil/therapeutic use , Photochemotherapy/methods , Precancerous Conditions/drug therapy , Skin Neoplasms/drug therapy , Transplantation/adverse effects , Administration, Topical , Aged , Aminolevulinic Acid/administration & dosage , Bowen's Disease/drug therapy , Bowen's Disease/etiology , Double-Blind Method , Female , Humans , Keratosis/drug therapy , Keratosis/etiology , Male , Middle Aged , Risk Factors , Treatment OutcomeSubject(s)
Aminolevulinic Acid/analogs & derivatives , Carcinoma, Basal Cell/drug therapy , Liver Transplantation , Nose Neoplasms/drug therapy , Photochemotherapy/methods , Photosensitizing Agents/administration & dosage , Administration, Topical , Aminolevulinic Acid/administration & dosage , Female , Humans , Middle Aged , Skin Neoplasms/drug therapy , Treatment OutcomeSubject(s)
Head and Neck Neoplasms/pathology , Histiocytoma, Benign Fibrous/pathology , Kidney Transplantation , 12E7 Antigen , Adult , Antigens, CD/analysis , Cell Adhesion Molecules/analysis , Diagnosis, Differential , Head and Neck Neoplasms/metabolism , Histiocytoma, Benign Fibrous/metabolism , Humans , Immunohistochemistry , Male , Vimentin/analysisABSTRACT
We describe two patients with a diagnosis of actinic prurigo who subsequently developed cutaneous B-cell lymphoma. This is the first report, to our knowledge, of this association. We propose that chronic antigenic stimulation by ultraviolet radiation, in the context of actinic prurigo, may have been causal in the development of these unusual lymphomas.
Subject(s)
Lymphoma, B-Cell/etiology , Photosensitivity Disorders/complications , Prurigo/complications , Skin Neoplasms/etiology , Child , Female , Humans , Lymphoma, B-Cell/pathology , Skin Neoplasms/pathologyABSTRACT
BACKGROUND: Viral warts may cause significant morbidity in individuals unable to mount an adequate T-helper 1 cell-mediated immune response to human papillomavirus. Imiquimod is a potent inducer of antiviral cytokine activity which has shown significant efficacy in the treatment of genital warts. Similar efficacy in cutaneous warts is not yet established. OBJECTIVES: To assess the response of persistent cutaneous warts to 5% imiquimod cream in immunosuppressed individuals. METHODS: Fifteen immunosuppressed patients with warts on the hands and/or feet present for more than 18 months, which had failed to respond to a minimum of 12 weeks of topical salicylic acid and four cycles of cryotherapy, were recruited. Imiquimod 5% cream was applied in an open label, right vs. left comparison study for 24 weeks (three times weekly for 8 weeks, daily for 8 weeks, then daily with occlusion for 8 weeks). RESULTS: Twelve (80%) patients completed the study protocol. Benefit was seen in five patients [36% in the intent-to-treat analysis (14 patients)], including more than 30% clearance of warts in three patients and reduction in overall size of warts in two further cases. Local skin reactions occurred in four (29%) patients and were usually mild. A transient rise in creatinine (11-29% above baseline) was measured in three renal transplant recipients, but we did not consider that this was related to imiquimod exposure. CONCLUSIONS: This is the first controlled study to assess therapeutic efficacy of topical 5% imiquimod cream in persistent warts associated with immunosuppression. It provides preliminary evidence that topical imiquimod may benefit a subgroup of immunosuppressed patients with recalcitrant cutaneous warts.
Subject(s)
Aminoquinolines/therapeutic use , Antiviral Agents/therapeutic use , Immunocompromised Host , Interferon Inducers/therapeutic use , Warts/drug therapy , Administration, Cutaneous , Adolescent , Adult , Aminoquinolines/adverse effects , Antiviral Agents/adverse effects , Female , Follow-Up Studies , Foot Dermatoses/drug therapy , Foot Dermatoses/pathology , Foot Dermatoses/virology , Hand Dermatoses/drug therapy , Hand Dermatoses/pathology , Hand Dermatoses/virology , Humans , Imiquimod , Interferon Inducers/adverse effects , Kidney Transplantation/immunology , Liver Transplantation/immunology , Male , Middle Aged , Prospective Studies , Recurrence , Self Administration , Treatment Outcome , Warts/immunology , Warts/pathologyABSTRACT
Tumour necrosis factor (TNF) is a pro-inflammatory cytokine with a role in the pathogenesis of a number of conditions including rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis and Crohn's disease. Etanercept (Enbrel; Immunex Corp., Seattle, WA, USA) is a recombinant soluble fusion protein of TNF-alpha type II receptor and IgG which acts by blocking the action of TNF-alpha. It is licensed for use in rheumatoid arthritis and juvenile chronic arthritis. A number of studies report the development of antinuclear and anti-double-stranded DNA antibodies in patients treated with TNF antagonists for rheumatoid arthritis. There are few reports of the development of clinical features of discoid, subacute or systemic lupus erythematosus. We present one of the first reported cases of etenercept-induced systemic lupus erythematosus and review the literature of lupus and TNF antagonists.